ERIC DOBMEIER - 30 Jan 2023 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC. (KDNY)

Signature
/s/ Kirk Schumacher, Attorney-in-Fact
Issuer symbol
KDNY
Transactions as of
30 Jan 2023
Net transactions value
-$792,869
Form type
4
Filing time
01 Feb 2023, 19:32:14 UTC
Previous filing
15 Dec 2022
Next filing
02 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KDNY Common Stock Options Exercise $10,500 +25,000 +9.2% $0.4200* 296,676 30 Jan 2023 Direct
transaction KDNY Common Stock Sale $613,612 -25,000 -8.4% $24.54 271,676 30 Jan 2023 Direct F1, F2
transaction KDNY Common Stock Options Exercise +24,999 +9.2% 296,675 31 Jan 2023 Direct F3
transaction KDNY Common Stock Sale $189,757 -7,688 -2.6% $24.68 288,987 31 Jan 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KDNY Stock Option (Right to Buy) Options Exercise $0 -25,000 -6.9% $0.000000 338,555 30 Jan 2023 Common Stock 25,000 $0.4200 Direct F5
transaction KDNY Stock Option (Right to Buy) Award $0 +255,150 $0.000000 255,150 31 Jan 2023 Common Stock 255,150 $25.27 Direct F6
transaction KDNY Restricted Stock Unit Award $0 +64,050 $0.000000 64,050 31 Jan 2023 Common Stock 64,050 Direct F7, F8
transaction KDNY Restricted Stock Unit Options Exercise $0 -24,999 -33% $0.000000 50,001 31 Jan 2023 Common Stock 24,999 Direct F7, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.27 to $24.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3 Restricted stock units (RSUs) convert into common stock on a one-for-one basis.
F4 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F5 The stock option vested as to 25% of the total shares monthly on March 6, 2021, and thereafter vests as to 1/48 of the total shares until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
F6 The stock option vests as to 25% of the total shares on January 31, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F7 Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F8 The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2024, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.
F9 The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.